20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the...
top of page
News
Search
- Nov 28
Come & meet us at JPM24!
Meet the 20Med Therapeutics team in San Francisco during #JPM2024 to discuss partnering opportunities around our PNP mRNA vaccine...
- Jul 6
Come & meet us!
We will present during a Drug Delivery Masterclass at the 3rd Annual mRNA-Based Therapeutics Summit, July 26-28 2023, Boston, United States
- Apr 18
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Enschede, The Netherlands, and Hampton, UK - April 18, 2023 – 20Med Therapeutics, a leader in non-viral delivery and development of gene...
- Feb 2
20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology
CEPI to initially provide up to USD850,000 to 20Med to advance development of 20Med’s bioresponsive polymeric nanoparticle platform for...
- Apr 14, 2022
20Med Therapeutics to Participate in the New Cancer Research Consortium Oncode-PACT
Leiden, 15 April 2022 - The National Growth Fund invests 325 million euro in the Oncode-PACT plan to accelerate the preclinical...
- Jun 1, 2021
20Med Therapeutics started research into mRNA vaccines against variants of the SARS-CoV-2 virus
The SARS-CoV-2 pandemic has shown the need to be prepared for an outbreak of an infectious disease. It spurred one of the most promising...
bottom of page